MEDXF (Medexus Pharmaceuticals) EPS without NRI: $0.01 (TTM As of Mar. 2026)


MEDXF Medexus Pharmaceuticals Inc MEDXF
58 GF Score
Price $3.67
GF Value $1.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals EPS without NRI?

Medexus Pharmaceuticals MEDXF +1.94% 58 EPS without NRI is $0.01 as of Mar. 2026. GuruFocus rates MEDXF with a GF Score™ of 58/100 and a GF Value™ of $1.32 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 786 Drug Manufacturers companies, Medexus Pharmaceuticals ranks worse than 127226.34% on this metric.

Medexus Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01.

During the past 12 months, Medexus Pharmaceuticals's average earnings per share (NRI) Growth Rate was -110.00% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Medexus Pharmaceuticals's EPS without NRI or its related term are showing as below:

During the past 13 years, Medexus Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 58.30% per year. The lowest was -913.80% per year. And the median was 12.00% per year.

MEDXF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Medexus Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.07.

Medexus Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was $-0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.07.


Medexus Pharmaceuticals  (OTCPK:MEDXF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Medexus Pharmaceuticals EPS without NRI Related Terms


Medexus Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals EPS without NRI Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.94 0.06 -0.04 0.15 -0.02

Medexus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.01 0.01 -0.00 0.02

MEDXF vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's PE Ratio without NRI falls into.


MEDXF
58GF Score
Medexus Pharmaceuticals Inc MEDXF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.01 mean?
Medexus Pharmaceuticals (MEDXF) has a EPS without NRI of $0.01 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medexus Pharmaceuticals and its competitors. According to the industry distribution chart, Medexus Pharmaceuticals ranks #999999 out of 786 companies in the Drug Manufacturers industry.
Is Medexus Pharmaceuticals' EPS without NRI too high?
Medexus Pharmaceuticals' current EPS without NRI is $0.01. The Drug Manufacturers industry median EPS without NRI is 9.60. Medexus Pharmaceuticals' value of $0.01 is 99.9% below this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #999999 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #999999 out of 786 companies for EPS without NRI. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 9.60. Medexus Pharmaceuticals' value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current EPS without NRI of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current EPS without NRI is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.67 — trading 178% above its estimated fair value. The current EPS without NRI is $0.01 and 99.9% below the Drug Manufacturers industry median of 9.60. Medexus Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current EPS without NRI is $0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of $3.67 is trading 178% above its estimated GF Value™ of $1.32. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEDXF:

  • EPS without NRI: $0.01
  • GF Value™: $1.32 vs. price of $3.67 (178% above fair value)
  • GF Score™: 58/100 with 6 warning signs
  • Industry Position: 99.9% below the Drug Manufacturers median (#999999 of 786)

No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medexus Pharmaceuticals Business Description

Other Exchanges P731:GermanyMDP:Canada
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
58GF Score

Get the complete analysis for MEDXF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.67
Price
$1.32
GF Value